Cite
Joseph RW, Elassaiss-Schaap J, Kefford R, et al. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res. 2018;24(20):4960-4967doi: 10.1158/1078-0432.CCR-17-2386.
Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W. J., Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O., Robert, C., Daud, A., Dronca, R., Hersey, P., Weber, J. S., Patnaik, A., de Alwis, D. P., Perrone, A., Zhang, J., Kang, S. P., Ebbinghaus, S., Anderson, K. M., & Gangadhar, T. C. (2018). Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clinical cancer research : an official journal of the American Association for Cancer Research, 24(20), 4960-4967. https://doi.org/10.1158/1078-0432.CCR-17-2386
Joseph, Richard W, et al. "Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 24,20 (2018): 4960-4967. doi: https://doi.org/10.1158/1078-0432.CCR-17-2386
Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res. 2018 Oct 15;24(20):4960-4967. doi: 10.1158/1078-0432.CCR-17-2386. Epub 2018 Apr 23. PMID: 29685882; PMCID: PMC6916264.
Copy
Download .nbib